Abstract
Transforming growth factor β (TGFβ) is present in blood of patients who do not respond to anti-programmed cell death (ligand) 1 [PD-(L)1] treatment, and through synergy with vascular endothelial growth factor (VEGF), it helps to create an environment that promotes tumor immune evasion and immune tolerance. Therefore, simultaneous inhibition of TGFβ/VEGF is more effective than targeting TGFβ alone. In this study, the dual inhibitory mechanism of TU2218 was identified through in vitro analysis mimicking the tumor microenvironment, and its antitumor effects were analyzed using mouse syngeneic tumor models. TU2218 directly restored the activity of damaged cytotoxic T lymphocytes (CTLs) and natural killer cells inhibited by TGFβ and suppressed the activity and viability of regulatory T cells. The inactivation of endothelial cells induced by VEGF stimulation was completely ameliorated by TU2218, an effect not observed with vactosertib, which inhibits only TGFβ signaling. The combination of TU2218 and anti-PD1 therapy had a significantly greater antitumor effect than either drug alone in the poorly immunogenic B16F10 syngeneic tumor model. The mechanism of tumor reduction was confirmed by flow cytometry, which showed upregulated VCAM-1 expression in vascular cells and increased influx of CD8 + CTLs into the tumor. As another strategy, combination of anti-CTLA4 therapy and TU2218 resulted in high complete regression (CR) rates in CT26 and WEHI-164 tumor models. In particular, immunological memory generated by the combination of anti-CTLA4 and TU2218 in the CT26 model prevented the development of tumors after additional tumor cell transplantation, suggesting that the TU2218-based combination has therapeutic potential in immunotherapy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Transforming growth factor β (TGFβ) signaling either inhibits or promotes cancer by regulating various downstream signaling systems. Moreover, TGFβ reduces the proliferation of cancer cells, which indicates that TGFβ hinders cancer progression [1, 2]. However, some studies have reported that TGFβ is overexpressed in cancer cells and involved in the development of cancer owing to its role in epithelial-to-mesenchymal transition [3, 4]. In addition, cancer patients with high TGFβ expression typically have a poor prognosis, and those who do not respond to anti-programmed death ligand 1 [PD-(L)1] therapy have high levels of TGFβ in the blood. Moreover, inhibition of TGFβ signaling in nonclinical experiments increased the efficacy of anti-PD-(L)1 therapy [5,6,7,8]. Based on this evidence, TGFβ has been classified as an immuno-anticancer therapeutic target, and the development of clinical TGFβ inhibitors has been actively underway, leading to the accumulation of many clinical studies [9,10,11]. According to the results of these studies, changes in the tumor microenvironment play important roles in cancer metastasis and growth [12]. Interestingly, TGFβ was found to have a greater effect on stromal and immune cells that surround tumors than on the cancer cells themselves [13]. These findings suggest that TGFβ can cause changes in the tumor microenvironment essential for cancer progression, and, from an immunotherapeutic point of view, this role can be important in the development of cancer therapeutics [13, 14].
As TGFβ exerts its cellular activity by binding to the transmembrane TGFβ type I receptor (also known as activin receptor-like kinase 5 (ALK5)) and type II receptor and forming heterodimer, selective inhibition of ALK5 can result in the blockade of TGFβ signaling cascades [15, 16]. ALK5 is ubiquitously expressed in immune cells, stromal cells, vascular endothelial cells, normal tissues, and tumor cells [17,18,19]. As a result of its ubiquitous expression, ALK5 alone is insufficient for understanding its clinicopathological role in cancer. Therefore, to clarify the role of ALK5 in the tumor microenvironment, an approach that identifies additional factors that are directly related to the activity of ALK5 and are strongly correlated with the development and severity of the disease was implemented. TGFβ is the most appropriate factor for determining the role of ALK5 [20]. Typically, compared with patients with a low TGFβ-ALK5 signature, cancer patients with an increased TGFβ-ALK5 signature exhibit a noticeable decrease in responsiveness to immune checkpoint inhibitors due to immune evasion and immune exclusion [21, 22]. In other words, from the perspective of immune evasion, ALK5 functions as a suppressor against antigen-presenting cells (APCs), cytotoxic T lymphocytes (CTLs), and natural killer (NK) cells involved in innate immunity and adaptive immunity and, conversely, acts as an activator of regulatory T cells [13]. In addition, from the perspective of immune exclusion, ALK5 acts on stromal cells in the intra- or extratumoral area to promote the formation of the stromal barrier, preventing T cells from infiltrating into the tumor and ultimately promoting refractory cancer and resistance to immunotherapy.
Vascular endothelial growth factor (VEGF) is a major factor that regulates tumor angiogenesis and creates a tumor microenvironment that is favorable for cancer growth by inactivating immune cells [23, 24]. The immunoregulatory property of VEGF can be attributed to the inhibition of dendritic cell differentiation, induction of regulatory T cell (Treg) growth, and inhibition of NK cell and CTL activity [25,26,27]. Through this immunomodulatory function, VEGF disrupts innate and adaptive immunity in the tumor microenvironment and helps tumors acquire immune evasion and tolerance [28]. In particular, in terms of angiogenesis and immunoregulation, VEGF exerts its effects via vascular endothelial growth factor receptor 2 (VEGFR2) [29]. VEGFR2 is widely expressed in vascular endothelial cells, immune cells, normal tissues, and tumor cells without specific restrictions [30]. In particular, vascular endothelial cells located around tumors are stimulated by various inflammatory cytokines and VEGF secreted from tumor cells and the surrounding immune cells, resulting in endothelial cell inactivation, which reduces the frequency of T cell transmigration from blood vessels into tumors to facilitate immune evasion [27, 31,32,33]. Inhibition of VEGFR2 has been shown to improve endothelial cell inactivation in tumors and increase the migration of CTLs to tumors, demonstrating that the main determinant of endothelial cell inactivation is suggested to be VEGFR2 in tumor vessel endothelial cells [34]. This hypothesis has been confirmed that combination therapy comprising a tyrosine kinase inhibitor that inhibits VEGFR2 and an anti-PD-(L)1 combination has innovative efficacy in various tumors [35,36,37], indicating that normalizing vascular immunity by inhibiting the VEGF-VEGFR2 axis is important for improving the efficacy of combination therapy with immune checkpoint inhibitors [33].
Immunosuppression is induced by the synergistic action of TGFβ and VEGF in the tumor microenvironment [38, 39]. In fact, TGFβ and VEGF are overexpressed in advanced cancer [5, 40, 41]. Unfortunately, no current therapeutic agent is capable of effectively inhibiting tumor growth by targeting TGFβ/VEGF. Therefore, a therapeutic agent simultaneously inhibiting TGFβ and VEGF is needed to improve the low response rate to anti-PD-(L)1 monotherapy. Additionally, since ALK5 and VEGFR2 are simultaneously expressed in key cells that are targets of immunotherapy, an efficient treatment strategy based on the mechanism of dual inhibition of ALK5 and VEGFR2 should be identified.
TU2218 is a small-molecule dual inhibitor that targets ALK5 and VEGFR2. Currently, TU2218 monotherapy and its combination with pembrolizumab have undergone phase 1 clinical trials, and phase 2a clinical trials will be conducted in 2024 (NCT05204862, NCT05784688). A pharmacokinetic analysis in a phase 1 clinical trial revealed that the clinical dose of TU2218 can reach to the concentration for inhibiting the phosphorylation of SMAD2 by more than 90%, and can exceed the effective concentration capable of mediating immunotherapeutic effects, and had high safety and tolerability [42]. In this study, we aimed to analyze the nonclinical characteristics of TU2218 related to immuno-oncology by evaluating its dual inhibitory mechanism and antitumor effects and investigated its efficacy in combination with various immune checkpoint inhibitors in a mouse syngeneic tumor model.
Results
TU2218 is a small-molecule inhibitor that inhibits dual ALK5/VEGFR2 signaling (Fig. 1a). The compounds exerted inhibitory effects on the ALK5 and VEGFR2 proteins at 1.2 nM and 4.9 nM, respectively, which differed from the inhibitory effects of vactosertib and galunisertib, as they inhibited only ALK5 (Fig. 1b). SMAD2 is a representative substrate protein used to measure the activity of ALK5 inhibitors as a sub-signaling protein of ALK5 [43]. TU2218 showed a half maximal inhibitory concentration (IC50) of 101 nM in the SMAD2 phosphorylation assay using human whole blood and an IC50 of 52.5 nM in the VEGFR2 phosphorylation assay in human umbilical vein endothelial cells (HUVECs) (Fig. 1c, d). Vactosertib and galunisertib were found to have no inhibitory effects on VEGFR2, even under cellular conditions (Fig. 1d).
TGFβ exerts immunosuppressive effects by inhibiting interferon γ (IFNγ) expression in CTLs [44]. In addition, since the effect of TGFβ on CTLs is the major cause of resistance to treatment with immune checkpoint inhibitors, identifying the inhibitory effect of TGFβ on CTLs is important for developing ALK5 inhibitors [7, 44,45,46]. When human peripheral blood mononuclear cells (PBMCs) stimulated with anti-CD3 antibodies were treated with TGFβ, the reduction in their number was accompanied by decreased IFNγ expression levels in CD4 + and CD8 + CTLs, and this immunosuppressive effect was completely restored by TU2218 treatment (Fig. 2a). The improvement in IFNγ secretion by inhibition of ALK5 activity was statistically significant after TU2218 treatment but not after vactosertib or galunisertib treatment. In addition, similar results were confirmed by analyzing IFNγ secretion in human PBMCs (Fig. 2b). ALK5 inhibition by TU2218 improves the TGFβ-elicited immunosuppression of not only CTLs but also NK cells. TGFβ is involved in lowering NK activity by downregulating the expression of natural killer group 2 member D (NKG2D) receptors, which are activation receptors on the surface of NK cells, and downregulated expression of NKG2D receptors is associated with a poor prognosis in patients with cancer [47, 48]. TU2218 treatment not only significantly upregulated the expression of TGFβ-reduced NKG2D receptors in human primary NK cells (CD56dim and CD56bright) and NK92 cells but also improved the cytotoxic activity of TGFβ-damaged NK cells (Fig. 2c, d, Supplementary figure S1a-g). Moreover, a decrease in IFNγ expression levels is observed in T cells in cocultures of human PBMCs and cancer cells [49]. Such immunosuppression can be explained by immune checkpoint activation resulting from the binding of the PD-L1 protein expressed on the surface of cancer cells with the PD1 protein present in lymphocytes in PBMCs [49]. In addition to direct stimulation by TGFβ, an immune-inactive environment is created by physical contact between cancer cells and immune cells in the tumor microenvironment. IFNγ secretion was significantly decreased when cancer cells such as MCF-7 or HT-1080 cells and PBMCs were cocultured compared to that when T cell receptors (TCRs) were activated in human PBMC monocultures. However, IFNγ secretion, which was reduced in cocultures of PBMCs and cancer cells, was completely restored by TU2218 treatment and improved in a TU2218 concentration-dependent manner (Fig. 2e). Interestingly, IFNγ secretion tended to be improved in response to the TGFβ neutralizing antibody, suggesting that TGFβ was secreted and activated immunosuppression when PBMCs and cancer cells were cocultured. Moreover, overexpression of coinhibitory receptors or defective costimulatory signal in the tumor microenvironment is another immune evasion mechanism [50]. We stimulated only CD3 in human PBMCs without CD28 stimulation, which resulted in the defective activation of costimulatory receptors. Compared with anti-CD3 stimulation alone, TU2218 treatment increased IFNγ secretion in both CD4 + and CD8 + T lymphocytes; this effect was confirmed to be superior to that of vactosertib (Fig. 2f).
TGFβ is secreted from CD4 + CD25 + Tregs and is involved in maintaining Foxp3 expression in Tregs in an autocrine- or paracrine-dependent manner, and its biological role is a critical for mediating Treg-based immunosuppressive action [51]. We analyzed the effects of TU2218 treatment on Treg activity using a Treg suppression assay. In the Treg suppression assay, the proliferation of effector T cells (CD4 + CD25-), which was reduced by coculture with Tregs, was restored in a TU2218 concentration-dependent manner. This effect was also confirmed with vactosertib, but the efficacy of TGFβ neutralizing antibody was marginal (Fig. 3a). Interestingly, TU2218 seems to regulate not only Treg function but also Treg viability (Fig. 3b), and a therapeutic strategy based on small molecules that directly inhibits the activity of ALK5 is expected to be more effective at overcoming the immunosuppressive environment of Tregs than biologic drugs that antagonize TGFβ.
TU2218 is a dual inhibitor that simultaneously inhibits ALK5 and VEGFR2 activity, and VEGFR2 inhibition by TU2218 is increased lymphocyte infiltration and improved endothelial cell inactivation. Recently, combination therapy with antiangiogenic agents and anti-PD-(L)1 blockade was confirmed to have breakthrough efficacy in various advanced carcinomas. The regulation of vascular-immune cross talk as a result of VEGFR activity suppression may be responsible for the successful combination treatment clinical trials, which is consistent with the effect of TU2218 on improving endothelial cell inactivation [27, 31,32,33, 35,36,37]. We experimentally mimicked the endothelial cell inactivation environment using human primary endothelial cells, HUVECs, and differentially expressed genes (DEGs) from TU2218 (an ALK5/VEGFR2 dual inhibitor), vactosertib (an ALK5 inhibitor), and ramucirumab (an anti-VEGFR2 antibody) treatments by microarray. As a result of the verified changes in 31,156 genes determined using 44,629 probes, 435 genes were identified as DEGs in TNFα and VEGF combination treatment compared to those in TNFα treatment. (Fig. 4a, b). DEGs were defined as those with a statistically significant 1.5-fold decrease or increase in gene expression. TU2218 treatment upregulated the expression of 123 genes and downregulated the expression of 79 genes against TNFα and VEGF combination treatment. The 123 upregulated genes included 10 common genes involved in cell adhesion. In addition, the 79 downregulated genes included 14 common genes involved in cell division (Fig. 4c). A comparative analysis of the distribution of 24 DEGs associated with cell adhesion and cell division functions using a volcano plot confirmed that the TU2218 and ramucirumab treatment groups had similar DEGs distribution, while that of the vactosertib treatment group was distinctly different from the other two groups (Fig. 4d). The difference in DEG distribution was explained by the degree to which each drug inhibited VEGFR2 activity. Among the analyzed DEGs, 10 with upregulated expression (VCAM-1, ICAM-1, COL8A1, IL-32, PDLIM1, CDON, CLDN11, CDH6, NRCAM, and BMX) and 14 with downregulated expression (NCAPH, PLK1, SPRY1, CENPE, PBK, DLGAP5, KIF20A, CDK1, CCNA2, NDC80, TPX2, NUSAP1, ANLN, and TOP2A) were verified using reverse transcriptase–polymerase chain reaction (Fig. 4e, f). A Venn diagram of the DEGs identified in the TU2218, vactosertib, and ramucirumab groups was constructed, and the results showed that the TU2218 group, which shared DEGs with the ramucirumab group, had a higher number of both upregulated and downregulated genes than the vactosertib group. In addition, when conducting a GO enrichment analysis on the shared genes between the TU2218 and ramucirumab groups, cell adhesion and cell division were found to be significantly enriched terms in the biological process category (Fig. 4g, h, Supplementary Tables S1, S2). In particular, according to the KEGG pathway analysis, ICAM-1 and VCAM-1 were confirmed to be significantly involved in cell adhesion (Fig. 4i).
The increase in the expression levels of these cell adhesion-related genes following TU2218 treatment and their involvement in improving endothelial cell inactivation was verified at the cellular level. In an experiment using HUVECs, ICAM-1 and VCAM-1 expression was downregulated after costimulation with TNFα and VEGF but significantly upregulated after TU2218 treatment. In contrast, ICAM-1 and VCAM-1 expression levels were not increased by vactosertib (Fig. 5a). To analyze the effect of TU2218 on cell adhesion, HUVECs were incubated with TNFα and VEGF and then cocultured with Jurkat T cells. The interaction between Jurkat T cells and HUVECs increased in response to TNFα stimulation alone but decreased in response to TNFα and VEGF costimulation. TU2218 treatment restored the reduced interaction between Jurkat T cells and HUVEC monolayers in a concentration-dependent manner, and this improvement in cell adhesion was mediated by VCAM-1, as confirmed by the use of a VCAM-1 neutralizing antibody (Fig. 5b, c, Supplementary figure S2a–e).
The in vivo antitumor efficacy of TU2218 was evaluated using a B16F10 syngeneic tumor model, which is a “cold” tumor type in which immune cells are deficient. Therefore, anti-PD1 therapy administered alone is unlikely to lead to significant therapeutic effects [52]. Considering these tumor characteristics, the B16F10 model was appropriate for confirming the synergistic effects of TU2218 and anti-PD1 on tumor-infiltrating lymphocyte (TIL) induction. Compared to the administration of anti-PD1 or TU2218 alone, a statistically significant reduction in tumor volume was observed after administration of the both anti-PD1 and TU2218. In addition, weight loss or toxicity due to drug administration was not observed during the drug administration (Fig. 6a, b). According to the flow cytometry analysis of tumor tissue, a significant increase in CD31 + VCAM-1 + cells was observed in the TU2218-administered group, and a significant increase in CD8 + T cells was observed in the anti-PD1 and TU2218-administered group (Fig. 6c).
TU2218 may be able to exert antitumor effects in combination with various other drugs. In particular, the clinical application of the combination of the anti-CTLA4 antibody and TU2218 is prioritized among the list of possible combination regimens. In the CT26 and WEHI-164 syngeneic models, high frequency of complete regression (CR) of tumor was observed in anti-CTLA4 and TU2218 combination group, showing 60% (6/10), and 80% (8/10) of CR, respectively (Fig. 7a–d). Especially in the CT26 model, anti-CTLA4 and TU2218 combination showed significant antitumor effect compared to anti-CTLA4 or TU2218 monotherapy (Fig. 7b), but not in WEHI-164 model (data not shown). In the B16F10 syngeneic models, a significant antitumor effect was confirmed in the combination administration group compared with the anti-CTLA4 or TU2218 monotherapy groups (Fig. 7e, f). In addition, a triple combination of anti-PD1 antibody, anti-CTLA4 antibody, and TU2218 was analyzed in the CT26 syngeneic model, which showed a significantly higher antitumor effect than the anti-PD1 and anti-CTLA4 combination (Fig. 7g, h).
Immunotherapy using immune checkpoint inhibitors is advantageous in terms of overall survival compared with chemotherapy or targeted therapy because of the formation of immunological memory, which prolongs clinical treatment efficacy [53, 54]. In the CT26 syngeneic tumor model, in which anti-CTLA4 and TU2218 were coadministered, complete regression was common, and a rechallenge assay was conducted to analyze whether immunological memory had been formed in these mice. After confirming CR by discontinuing drug administration, CT26 cells were transplanted into age-matched and CR-confirmed groups without additional drug administration (Fig. 8a, b). While tumors developed in every age-matched mouse, tumor formation was perfectly suppressed in the CR-confirmed individuals. In addition, the percentage of CD4 + and CD8 + effector memory T cells in the spleen was greater in the CR-confirmed group than the age-matched group (Fig. 8c, Supplementary figure S3a–c). Overall, these results demonstrate that TU2218-based combination strategies promote the formation of immunological memory.
Discussion
The development of small-molecule compounds, antibodies, and fusion proteins that can target TGFβ has been ongoing for decades [55,56,57]. In the early stage of development of TGFβ inhibitors as anticancer drugs, the focus was on targeted anticancer agent for suppressing the growth of cancer cells through the regulation of TGFβ signaling; however, such a possibility has been demonstrated at a nonclinical level only [1, 2]. However, a deeper understanding of the tumor microenvironment owing to the development of immunotherapy led to the identification of TGFβ, which plays an important role in enabling cancer cells to escape the immune system by activating and differentiating the surrounding immune cells [13, 14, 44]. Furthermore, in a retrospective analysis of patients treated with anti-PD-(L)1 therapy, high levels of TGFβ were detected in the blood of patients who did not respond to anti-PD-(L)1 antibodies [8]. Additionally, inhibition of TGFβ signaling in nonclinical experiments has shown an increase in the efficacy of anti-PD-(L)1 antibodies [7]. These findings explain why TGFβ blockers should be developed as immune-related anticancer agents.
Analyzing the effect of TGFβ inhibitors on immunity is essential for understanding the mechanism of anticancer action, determining the effective concentration of drugs in the tumor microenvironment, and identifying unexpected off-target variables. Galunisertib is a representative small-molecule inhibitor of ALK5, and its effect has been analyzed in various immune cells [55]. Galunisertib treatment can improve TGFβ-mediated inhibition of CD8 + T lymphocyte proliferation and IFNγ expression and Treg-mediated inhibition of naïve T lymphocyte proliferation [58]. Galunisertib can also upregulate the expression of GzmB and IFNγ suppressed by TGFβ in NK cells [59]. The confirmed effective concentration that affects immune cells can be used to determine the appropriate dose during clinical development and for interpreting clinical efficacy. In contrast to vactosertib, galunisertib, and TGFβ neutralizing antibody drugs, TU2218 showed increased efficacy in improving endothelial cell inactivation and CTL activity. In addition, pharmacokinetic analysis proved that the current clinical administration dose of TU2218 can reach to the sufficient effective concentration for increasing CTL and NK activity and suppressing Tregs [42].
Anti-PD-(L)1 therapy has been shown to be effective in treating various cancer types. However, as monotherapy has a weak response rate, the need for combination therapy has emerged. The development of combination chemotherapy and targeted antiangiogenic drugs has significantly progressed [35,36,37, 60, 61]. In addition, an approach for discovering and resolving the cause of the low response to anti-PD-(L)1 therapy has been developed [62, 63]. The reduced IFNγ secretion observed in the coculture of PD-L1-expressing cancer cells and TCR-stimulated PBMCs was expected to be increased by pembrolizumab or atezolizumab treatment [49]. However, in our system, IFNγ secretion was not improved by the two immune checkpoint inhibitors, as shown in Fig. 2e. Interestingly, a clear recovery was observed with TU2218, and in particular, a tendency to improve IFNγ secretion by TGFβ neutralizing antibody was observed despite the absence of additional TGFβ stimulation. These findings suggest that TGFβ secreted in the presence of both cancer and immune cells can contribute to resistance to pembrolizumab and atezolizumab and may be related to the high expression of TGFβ in patients who do not respond to anti-PD-(L)1 treatment [7, 8]. Therefore, TGFβ signaling blockade by ALK5 inhibitors can be used as a breakthrough treatment for refractory and resistant patients to immune checkpoint inhibitors.
Tumors of the immune desert type are known to have low reactivity to anti-PD-(L)1 antibody drugs compared to inflamed type tumors. Major reasons for poor reactivity include low antigen presentation ability of tumor cells, limitation of penetration of immune cells due to activated stromal cells, reduction of intravascular adhesion proteins around tumors, and effect by chemokine [64]. The B16F10 syngeneic model is a representative immune desert model and was used to demonstrate the combination efficacy of TU2218 and anti-PD1 in Fig. 6. The background of statistically significant tumor reduction in the group administered with TU2218 and anti-PD1 antibodies compared to the anti-PD1 antibody administration group can be explained by positive correlation between an increase of adhesion molecules in vascular endothelial cells in tumors and infiltrated cytotoxic T lymphocyte in tumors. In addition to, role of chemokines has been reported to be involved in the process of recruitment of T lymphocyte into tumors. In particular, it has been reported that inhibition of TGFβ signaling increases CXCL9/10 in cancer-associated fibroblast subset, enhancing the infiltration of antigenic CD8 T lymphocyte in tumors [65], and CCL5 is known to induce apoptosis of CD8 T lymphocyte due to regulatory T lymphocyte by utilizing TGFβ as an effector [66]. Overall, the elevation of infiltrated T lymphocyte in tumors by TU2218 can be interpreted as a result of controlling both the adhesion molecule of endothelial cells and the chemokines in the tumor microenvironment. Incidentally, it is well known that the B16F10 syngeneic model hardly reacts with anti-PD1 alone, but the background of partial response derived with anti-PD1 alone in Fig. 6 seems to be related to starting drug administration at a palpable tumor size of less than 50 mm3. Several studies using the B16F10 syngeneic model also confirmed the partial efficiency of anti-PD1 alone to a similar level [67,68,69].
Our results provide evidence to explain the synergistic compatibility and clinical effects of the combination of TU2218 and anti-PD-(L)1 agent. Two representative functions of TU2218 that support synergy with anti-PD-(L)1 therapy are the inhibition of Treg activity, which is governed by TGFβ-ALK5, and the induction of TILs through improvements in endothelial cells, which are governed by VEGF-VEGFR2. In fact, a multityrosine kinase inhibitor that inhibits VEGFR2, or ipilimumab, which inhibits Treg activity, combined with anti-PD1 therapy has shown clinical benefits in several cancers [35]. This finding demonstrates that overcoming immune evasion and immune tolerance caused by VEGFR2 and TGFβ in the tumor microenvironment is essential for ensuring clinical efficacy. In addition, we are interested in a clinical study on the combination of ipilimumab and pembrolizumab in patients with melanoma that are unresponsive to anti-PD-(L)1 therapy [70]. Our focus in this clinical trial was that a meaningful response of 7.2% CR and 21.4% partial regression was induced in PD-(L)1 therapy-resistant patients. Moreover, the anti-CTLA4 antibody-based combination strategy could be a breakthrough for patients who are resistant to anti-PD-(L)1 therapy [70]. In syngeneic tumor models, we observed that the combination of TU2218 and an anti-CTLA4 antibody not only induced tumor CR but also completely eradicated repeated tumor challenges through the formation of immunological memory. This combination option is valuable and may be developed as a therapeutic alternative in the future for patients unresponsive to anti-PD-(L)1 therapy.
Overall, TU2218 is a dual inhibitor that simultaneously inhibits ALK5 and VEGFR2 and is expected to create a favorable environment for immune checkpoint inhibitors to act by controlling various immunosuppressive factors in the tumor microenvironment. This mechanism of action of TU2218 may overcome the limitations of immune checkpoint inhibitor monotherapy.
Materials and methods
Reagent
The ALK5 inhibitor TU2218, vactosertib, or galunisertib was obtained from TiumBio (Gyeonggi-do, Korea, TU2218 was developed by TiumBio, and phase 1a, the monotherapy of TU2218, has been terminated and phase 1b, a combination study with pembrolizumab, is nearing the end. A combination study of phase 2a with pembrolizumab is scheduled in the third quarter of this year (NCT05204862, NCT05784688)), BLD Pharmatech (Shanghai, China), or Crysdot (Bel Air, MD USA). Recombinant human TGFβ, VEGF, and anti-TGFβ neutralizing antibody (clone 1D11) were obtained from R&D systems (Minneapolis, MN, USA). Pembrolizumab, atezolizumab, and ramucirumab were obtained from Selleckchem (Houston, TX, USA). For in vivo administration, anti-mouse PD1 (clone RMP1-14) and anti-mouse CTLA4 antibodies (clone 9D9) were obtained from BioXCell (Lebanon, NH, USA). Anti-CD3/CD28 coated-microbead was prepared from T cell activation/expansion kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s protocol. Fetal bovine serum (FBS) was obtained from SERANA (Brandenburg, Germany). Phospho-buffered saline (PBS), Hanks' balanced salt solution (HBSS), and trypsin–EDTA were provided from Lonza (Basel, Switzerland) or Thermo Fisher Scientific (Massachusetts, USA).
Cell culture
Human PBMCs were purchased from STEMCELL Technology (Vancouver, Canada). Cells were cultured with RPMI-1640 media (Welgene, Gyeongsangbuk-do, Korea) containing 10% heat-inactivated FBS. MCF-7, HT-1080, K562, and Jurkat T cells were obtained from Korean Cell Line Bank, KCLB (Seoul, Korea). NK92mi, CT26, and HUVEC were obtained from American Type Culture Collection, ATCC (Manassas, VA, USA). Cells were incubated at 37℃, 5% CO2 humidified incubator.
Enzyme assay for ALK5 and VEGFR2
Each compound was tested against indicated kinases (Reaction Biology Corporation, Malvern, PA, USA). Compounds were treated to 10 points with a threefold serial dilution starting at 10 μM or 100 μM. Enzyme reactions were performed with 10 μM ATP and buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, (2 mM MnCl2 if applicable), 1 mM EGTA, 0.02% Brij 35, 0.02 mg/ml bovine serum albumin (BSA), 0.1 mM Na3VO4, 2 mM DTT, and 1% DMSO) for 2 h.
Phospho-SMAD2/SMAD2 assay
Human whole blood was treated with various concentration of TU2218 and 5 ng/mL of TGFβ was stimulated for additional 30 min. Reaction was stopped with Lyse/Fix buffer (BD bioscience, NJ, USA) and cells were permeabilized by Perm III buffer (BDbioscience) and stained using the following antibodies: anti pSMAD2(Ser465/467)/SMAD3(pS423/pS425)-PE (clone O72-670, BD Bioscience) or anti-SMAD2-AF647 (clone D43B4, Cell Signaling, Danvers, MA, USA). Stained cells were analyzed with CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA) and data were analyzed by Cytpert or Prism 5 software (GraphPad, Boston, MA, USA). The relative ratio of pSMAD2/SMAD2 was calculated using the following equation (pSMAD2 of vehicle = 0%, pSMAD2 of TGFβ = 100%).
All human samples were prospectively obtained under written informed consent. All study protocols were approved by the Institutional Review Board of Tiumbio Co., Ltd (IRB code: TBIRB-22-BR-001).
Phospho-VEGFR2/VEGFR2 assay
The HUVECs were seeded on gelatin (Sigma, St. Louis, MO, USA)-coated 12-well plates. Cells were starved for overnight and treated with various concentration of compound for 1 h and then stimulated with 20 ng/mL VEGF for 15 min. Cells were lysed in RIPA buffer (Sigma) containing protease inhibitors (cOmplete mini, EDTA-free; Roche, Basel, Switzerland) and phosphatase inhibitor cocktail (PhosStop, Roche). Lysates were analyzed to immunoblotting assay using anti-phospho VEGFR2 antibodies (clone 19A10, Cell Signaling) and anti-VEGFR2 (clone D5B1, dilution 1: 1000) (Cell Signaling). Semiquantitative densitometry was performed using Image J software (NIH, Bethesda, MD, USA). And IC50 was calculated to Prism 5 Software.
TGFβ-induced immune suppression
PBMCs were seeded on 96-well plate and treated with various concentration of test drugs with 5 or 50 ng/mL TGFβ, and anti-CD3/CD28 microbead. To analyze intracellular IFNγ, PBMCs were incubated with adding Golgistop (BD bioscience) before collection of cells and stained with the following antibodies (surface): anti-human CD3-APC-Cy7 (clone UCHT1), anti-human CD8a-AF700 (clone RPA-T8), and anti-human CD4-PE-Cy7 (clone RPA-T4), anti-human IFNγ-PE-CF594 (clone B27, Biolegend). To measure secreted-IFNγ, supernatants were analyzed by IFNγ ELISA kit (Thermofisher Scientific). To detect compound effect on natural killer (NK) cell in PBMC or NK92mi, cells were stimulated with 5 ng/mL TGFβ with various concentration of test drugs. Cells were stained by anti-human NKG2D-PE (clone 1D11) and anti-human CD56-PB (clone 5.1H11). Expression pattern of NK2GD was analyzed on CD56 bright or CD56 dim population. Data were analyzed by Cytpert or Flow Jo v10.7.2 (FlowJo, Ashland, OR, USA).
Coculture
Human PBMCs were cocultured with MCF-7 or HT-1080 at 2:1 or 4:1 ratio respectively, and treated with various concentration of test drugs, and followed by adding anti-CD3/CD28 microbead. The supernatant was collected after 48 h and applied to IFNγ ELISA method (Invitrogen). Preincubated-NK92mi cells with TGFβ and test drug were cocultured with CFSE(Invitrogen)-labeled K562 cells at ratio 2:1 for 24 h and cytocidal activity of NK92mi cells was analyzed to quantification of CFSE-labeled K562 using flow cytometry.
Treg suppression assay
Regulatory T cell (Treg) and effector T cell (Teff) were isolated from pooled PBMCs from 8 healthy donors using CD4 + CD25 + Regulatory T cell isolation kit (Miltenyi Biotec) according to manufacturer’s protocol. CFSE-labeled Teff was incubated on 96-well with Treg cells at 1:3 ratio, with various concentration of test drugs. All cells were stimulated with anti-CD3/CD28 microbead for 5 days. To measure Teff proliferation, cells were stained with anti-human CD25-PE (clone BC96, Biolegend) and CFSE dilution was analyzed using flow cytometry.
Endothelial cell inactivation
HUVECs were starved in serum-free EBM-2 media for overnight and treated with various concentration of test drugs and then stimulated with 100 ng/mL VEGF and 0.04 ng/mL TNFα (Peprotech, New Jersey, US). To analyze the level of surface ICAM-1 and VCAM-1, cells were stained with anti-human ICAM-1-PE (clone HA58) and anti-human VCAM-1-APC (clone STA) (Biolegend). The expression level of ICAM-1 and VCAM-1 was measured to flow cytometry. The relative ICAM-1(%) or VCAM-1(%) was calculated using the following equation (TNFα = 100%).
To analyze binding activity of Jurkat on anergic HUVECs, the pre-treated HUVECs with VEGF and TNFα were cocultured with CFSE-labeled Jurkat cells at 1:1 ratio for 25 min. And then unbound Jurkat cells were washed and bound Jurkat cells were harvested to 0.05% trypsin–EDTA. CFSE-labeled Jurkat cells were isolated on HUVECs and Jurkat mixture to flow cytometry.
Microarray analysis
Microarray was conducted using GeneChip Human Gene 2.0ST Array platform (Macrogen Corporation, Seoul, Korea). RNA samples were obtained from triplicate repeated-experiments. Total RNA was extracted from HUVECs using Direct-zol RNA MiniPrep (Zymoresearch, Irvine, CA, USA) according to the manufacturer’s recommendations. Complementary DNA (cDNA) was synthesized using the GeneChip WT (Whole Transcript) Amplification kit as described by the manufacturer. The sense cDNA was then fragmented and biotin-labeled with TdT (terminal deoxynucleotidyl transferase) using the GeneChip WT Terminal labeling kit. Approximately 5.5 μg of labeled DNA target was hybridized to the Affymetrix GeneChip Array at 45 °C for 16 h. Hybridized arrays were washed and stained on a GeneChip Fluidics Station 450 and scanned on a GCS3000 Scanner (Affymetrix). The probe cell intensity data computation and a CEL file generation were performed using Affymetrix® GeneChip Command Console® Software (AGCC). Differentially expressed genes (DEGs) data were considered significant if both the p value ≤ 0.05, fold change (FC) < -1.5 or > 1.5 after normalization using AGCC. The gene ontology (GO) annotations of the DEGs were downloaded from the DAVID Bioinformatics Resources (https://david.ncifcrf.gov). The pathway analysis was obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http:// www.genome.jp/kegg). qRT-PCR was performed using iQ SYBR Green Supermix (BioRad, Hercules, CA, USA) following the instructions. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene. Data were examined by the 2-ΔΔCt method. Primers for qRT-PCR are listed in the Supplementary Table S3.
Syngeneic mouse tumor models and tumor tissue analysis
C57BL6 and BALB/c female mice between 6 and 8 weeks were obtained OrientBio (Gyeonggi-do, Korea) or Vital River Laboratories Research Models and Services (Beijing, China). Each mouse was subcutaneously inoculated with B16F10(3 × 105 cells), CT26(5 × 105 cells), and WEHI-164(1 × 106 cells) tumor cells in the flank. When tumor size reached approximately 30–60 mm3, mice were randomized and then drug treatments were continued for indicated periods. Tumor size was measured three times a week and calculated by the following formula: Volume = (Length × Width × Width)/2. Mice were housed under pathogen-free condition with a maximum of 5 per cage. For Fig. 7d, increase/decrease percentage analysis of tumor volume at day 17 was calculated by the following equation:
Biopsied tumor tissues were dissociated with Tumor dissociation kit (Miltenyi Biotec) and gentleMACS (Miltenyi Biotec). Erythrocytes were lysed and single-cell suspensions were incubated with Fc block and stained with the following antibodies: anti-mouse CD31-FITC (clone 390, eBioscience), anti-mouse VCAM-1-APC (clone 429, Biolegend) anti-mouse CD45-BV510 (clone 30-F11, BD Bioscience), anti-mouse CD3-APC-Cy7 (clone 145-2C11, Invitrogen), anti-mouse CD8-BB515 (clone 53–6.7, BD Bioscience), and anti-mouse IFNγ-APC (clone XMG1.2, BD Bioscience). Samples were analyzed to flow cytometer and data were analyzed by Cytpert or FlowJo v10.7.2.
To detect immunological memory activity, both complete regressed-mice of TU2218 plus anti-CTLA4 mAb combination group and age-matched mice were rechallenged with CT26 (5 × 105 cells) on the opposite flank. And then tumor generation and size were observed without drug treatment. For immune profiling of spleen tissue, spleens were harvested and mechanically dissociated to acquire single-cell suspensions using a plunger. Cells were stained with following antibodies: anti-mouse CD45-BV510 (clone 30-F11, BD Bioscience), anti-mouse CD3-APC-Cy7 (clone 145-2C11, Invitrogen), anti-mouse CD8-BB515 (clone 53–6.7, BD Bioscience), anti-mouse CD4-PE-Cy7 (clone RM4-5, BD Bioscience), anti-mouse CD44-PE (clone IM7, BD Bioscience), and anti-mouse CD62L-APC (clone MEL-14, Biolegend). Samples were analyzed to flow cytometer and data were analyzed by FlowJo v10.7.2. All protocols for animal models were approved by the Institutional Animal Care and Use Committee (IACUC) of Chaon Inc (Gyeonggi-do, Korea) or Crown Bioscience Inc. (Beijing, China).
Statistical and data analysis
All statistical analyses were processed using GraphPad Prism 5 (Boston, MA). Statistical analysis with multiple groups was completed using one-way ANOVA with post hoc Tukey test or two-way ANOVA with post hoc Bonferroni test. Data are represented as the mean with error bars signifying the standard error of the mean (SEM) unless otherwise indicated. Statistical significance is indicated as *p < 0.05, **p < 0.01, ***p < 0.001. Gating strategy and representative FCM graph were included in indicated Supplementary figures.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The microarray data from this research are available at GEO accession number GSE239760 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE239760).
Abbreviations
- ANLN:
-
Anillin, actin binding protein
- b.i.d:
-
Two times a day
- BMX:
-
BMX non-receptor tyrosine kinase
- COL8A1:
-
Collagen type VIII alpha 1 chain
- CDON:
-
Cell adhesion associated, oncogene regulated
- CLDN11:
-
Claudin-11
- CENPE:
-
Centromere protein E
- CDK1:
-
Cyclin-dependent kinase 1
- CCNA2:
-
Cyclin A2
- CDH6:
-
Cadherin-6
- DLGAP5:
-
DLG-associated protein 5
- Foxp3:
-
Forkhead box P3
- GzmA:
-
Granzyme A
- GzmB:
-
Granzyme B
- ICAM-1:
-
Intercellular adhesion molecule 1
- IL-32:
-
Interleukin 32
- KIF20A:
-
Kinesin family member 20A
- NRCAM:
-
Neuronal cell adhesion molecule
- NCAPH:
-
Non-SMC condensin I complex subunit H
- NDC80:
-
NDC80 kinetochore complex component
- NUSAP1:
-
Nucleolar and spindle-associated protein 1
- PDLIM1:
-
PDZ and LIM domain 1
- PLK1:
-
Polo-like kinase 1
- PBK:
-
PDZ binding kinase
- SDS-PAGE:
-
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
- SPRY1:
-
Sprouty RTK signaling antagonist 1
- TPX2:
-
TPX2 microtubule nucleation factor
- TOP2A:
-
DNA topoisomerase II alpha
- TNFα:
-
Tumor necrosis factor α
- VCAM-1:
-
Vascular cell adhesion molecule 1
- qRT-PCR:
-
Real-time quantitative reverse transcription PCR
References
Massagué J (2008) TGFβ in cancer. Cell 134:215–230
Becker C et al (2004) TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491–501
Xu J, Lamouille S, Derynck R (2009) TGF-β-induced epithelial to mesenchymal transition. Cell Res 19:156–172
Hao Y, Baker D, Ten Dijke P (2019) TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci 20:2767
von Rahden BH et al (2006) Overexpression of TGF-β1 in esophageal (Barrett’s) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinogenesis: Published in Cooperation with the University of Texas MD Anderson Cancer Center 45:786–794
Martin CJ, et al (2020) Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci Translat Med 12:eaay8456
Mariathasan S et al (2018) TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544–548
de Miguel-Perez D et al (2023) Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer. Cancer 129:521–530
Kim TW, et al. (Wolters Kluwer Health, 2021)
Spira A et al (2023) Bintrafusp alfa: a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated colorectal cancer: results from a phase I trial. Oncologist 28:e124–e127
Hanna GJ, et al (2023) American Society of Clinical Oncology, 2023
Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P (2021) The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers 13:2053
Derynck R, Turley SJ, Akhurst RJ (2021) TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol 18:9–34
Pickup M, Novitskiy S, Moses HL (2013) The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 13:788–799
Su J-X et al (2023) Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies. Acta Pharmacol Sin. https://doi.org/10.1038/s41401-023-01093-8
Kim B-G, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ (2021) Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol 14:1–20
Castañares C et al (2007) Signaling by ALK5 mediates TGF-β-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J Cell Sci 120:1256–1266
Monsivais D, Peng J, Kang Y, Matzuk MM (2019) Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma. Proc Natl Acad Sci 116:3883–3892
Ni N et al (2018) Glandular defects in the mouse uterus with sustained activation of TGF-beta signaling is associated with altered differentiation of endometrial stromal cells and formation of stromal compartment. PLoS ONE 13:e0209417
Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577–584
Nakazawa N et al (2020) High stromal TGFBI in lung cancer and intratumoral CD8-positive T cells were associated with poor prognosis and therapeutic resistance to immune checkpoint inhibitors. Ann Surg Oncol 27:933–942
Grivas P, et al (2019) American Society of Clinical Oncology
Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13:871–882
Albini A, Bruno A, Noonan DM, Mortara L (2018) Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol 9:527
Dikov MM et al (2005) Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174:215–222
Wada J et al (2009) The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 29:881–888
Zhao Y et al (2022) VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment. Int J Biol Sci 18:3845
Bourhis M, Palle J, Galy-Fauroux I, Terme M (2021) Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment. Front Immunol 12:616837
Zhu P, Hu C, Hui K, Jiang X (2017) The role and significance of VEGFR2+ regulatory T cells in tumor immunity. OncoTargets Ther 4315–4319
Ho QT, Kuo CJ (2007) Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 39:1349–1357
Lee WS, Yang H, Chon HJ, Kim C (2020) Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med 52:1475–1485
Song Y et al (2020) Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol 11:1956
Goel S et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121
Tada Y et al (2018) Targeting VEGFR2 with Ramucirumab strongly impacts effector/activated regulatory T cells and CD8+ T cells in the tumor microenvironment. J Immunother Cancer 6:1–14
Llovet JM, et al (2019) American Society of Clinical Oncology
Rini BI et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127
Finn RS et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905
Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P (2009) Transforming growth factor-beta 1 (TGF-β1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 219:449–458
Courau T, et al (2016) TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight 1
Langenskiöld M, Holmdahl L, Falk P, Angenete E, Ivarsson ML (2008) Increased TGF-Beta1 protein expression in patients with advanced colorectal cancer. J Surg Oncol 97:409–415
Latil A et al (2000) VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 89:167–171
Shin H, et al (2023) BMJ Specialist Journals
Farrington D et al (2007) Development and validation of a phosphorylated SMAD ex vivo stimulation assay. Biomarkers 12:313–330
Dahmani A, Delisle J-S (2018) TGF-β in T cell biology: implications for cancer immunotherapy. Cancers 10:194
Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD (2018) TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun 9:4692
Thorsson V, et al (2018) The immune landscape of cancer. Immunity 48:812–830 (2018)
Peng Y-P et al (2013) Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med 11:1–10
Liu H et al (2019) Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res 9:2064
Zheng Y, Fang YC, Li J (2019) PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett 18:5399–5407
O’Neill RE, Cao X (2019) Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res 143:145–194
Fu S et al (2004) TGF-β induces Foxp3+ T-regulatory cells from CD4+ CD25− precursors. Am J Transplant 4:1614–1627
Yu JW et al (2018) Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE 13:e0206223
Ribas A et al (2012) New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 18:336–341
Klebanoff CA, Gattinoni L, Restifo NP (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211:214–224
Herbertz S, et al (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Design Development and Therapy, 4479–4499
Morris JC et al (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9:e90353
Lan Y, et al (2018) Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Translat Med 10:eaan5488
Holmgaard RB et al (2018) Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer 6:1–15
Yingling JM et al (2018) Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. Oncotarget 9:6659
Gandhi L et al (2018) Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 378:2078–2092
Liu Z et al (2023) Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study. Sci Rep 13:3385
Tawbi HA et al (2022) Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386:24–34
Cho BC et al (2022) Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 23:781–792
Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 52:17–35
Grauel AL et al (2020) TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. Nat Commun 11:6315
Chang L-Y et al (2012) Tumor-derived chemokine CCL5 enhances TGF-β–mediated killing of CD8+ T cells in colon cancer by T-regulatory cells. Can Res 72:1092–1102
Vijayakumar G, Palese P, Goff PH (2019) Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine 49:96–105
Ali LR, et al (2023) PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. J Exp Med 220
Gupta A et al (2021) Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. Commun Biol 4:1296
Olson DJ et al (2021) Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J Clin Oncol 39:2647–2655
Acknowledgements
This research was supported by Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (RS-2022-00167091, Republic of Korea). The authors would like to thank all researchers at TiumBio who contributed and devoted themselves to the development of TU2218.
Funding
This research was supported by Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (RS-2022–00167091, Republic of Korea).
Author information
Authors and Affiliations
Contributions
Nam-Hoon Kim designed the research, performed the in vitro and in vivo experiments, analyzed data, drafted, wrote, and edited the paper. Jihyun Lee performed the in vitro and in vivo experiments, analyzed data, and wrote the manuscript. Seung-Hyun Kim and Seong-Ho Kang performed the in vitro and in vivo experiments and analyzed data. Chan-Hee Yu was involved in in vivo drug administration. Sowon Bae did the literature search. Jeongmin Seo was involved in enzymatic assay. Hun-Taek Kim is the CEO of TiumBio Co., Ltd., and was responsible for all works. The authors read and approved the final manuscript. These authors contributed equally: Nam-Hoon Kim and Jihyun Lee.
Corresponding author
Ethics declarations
Conflict of interests
The authors have no relevant financial or non-financial interests to disclose.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Ethics declarations
For all experiments involving human or animal subjects, experiments were approved by the appropriate institutional committee prior to execution, and conducted according to the pertinent guidelines and regulations. The animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Chaon Inc. (Gyeonggi-do, Korea) (CE22097, CE21325, CE21256) or Crown Bioscience Inc. (Beijing, China) prior execution. All experiments were conducted according to the pertinent guidelines and regulations implemented by IACUC. The authors complied with the ARRIVE guidelines. All human samples were prospectively obtained under written informed consent. All study protocols were approved by the Institutional Review Board of Tiumbio Co., Ltd (IRB code: TBIRB-22-BR-001).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kim, NH., Lee, J., Kim, SH. et al. ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects. Cancer Immunol Immunother 73, 190 (2024). https://doi.org/10.1007/s00262-024-03777-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00262-024-03777-4